A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability is a research paper published in Cancer (2021). On theSindex it has a DataRank of 2.4. It has been cited 80 times, with 74 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.659
From this paper's citation signal
Citation Network Contribution
1.8
From 57 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 74 citers.
NIH Clinical Center
Grant: CA‐16359
NIH Clinical Center
Grant: U01 CA176067‐01
NIH Clinical Center
Grant: CA-16359
NCATS NIH HHS
Grant: UL1 TR001863
NCI NIH HHS
Grant: U01 CA176067
National Research Foundation of Korea
Grant: NRF-2019R1A4A102900
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P30 CA016359
Honorable Tina Brozman Foundation
Merck
Stand Up To Cancer
Fondazione Guido Berlucchi
Gilead Sciences
FWCI
6.97
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals